ArticleFrontiers in microbiology2026
Modified Jiaoqi powder ameliorates ulcerative colitis through gut microbiota-tryptophan metabolism-AhR signaling modulating-ILC2/ILC3 balance.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gut microbiota in asthma: mechanisms, clinical evidence, and therapeutic opportunities.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ulcerative colitis (UC) occurs as a result of the interaction among intestinal microbiota, the intestinal barrier, and the immune system. The current treatment options have their limitations and come with side effects, thus there is an urgent need to develop new drug candidates for the treatment of UC. Modified Jiaoqi powder (MJQP) is a Traditional Chinese Medicine formulation improved from an empirical prescription prescribed by Tietao Deng, a celebrated master of Traditional Chinese Medicine. Although MJQP is a viable alternative medication for treating UC, the underlying mechanism is unclear yet. Methods: Eight groups were designed: control, model, mesalazine group (400 mg/kg), MJQP low-, medium-, and high-dose (2.5, 5, 10 g/kg), AhR antagonist CH223191 (10 mg/kg) combined administration with MJQP (5 g/kg), and CH223191 group (10 mg/kg). The efficacy of MJQP was evaluated using the disease activity index (DAI), colonic length, and pathological alterations. RT-PCR, western blotting, alcian blue staining, immunofluorescence and transmission electron microscopy were used to detect tight junction proteins. The proportion and function of ILC2 and ILC3 were detected by flow cytometry and ELISA, and AhR signaling was examined by western blotting and RT-PCR. 16S rDNA sequencing and targeted tryptophan metabolite detection were used to detect the intestinal microflora and tryptophan metabolites. Results: MJQP substantially restored body weight and colonic length in UC, and reduced DAI and colonic pathological alterations, while MJQP restored tight junctions of the colon to repair the intestinal barrier. Moreover, MJQP increased the levels of IL-22 and the proportion of IL-22 Conclusion: MJQP repaired the damaged intestinal barrier to facilitate the resolution of chronic colitis by modulating AhR-mediated ILC2/ILC3 balance through gut microbiota-related tryptophan metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.